Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending August 2012. The report details a specific share repurchase transaction executed on August 2, 2012, in accordance with shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 900,000 Ordinary Shares of 25 pence each.
- Purchase Date: August 2, 2012.
- Price Range: Highest price paid was 1,499 pence per share; lowest price paid was 1,482 pence per share.
- Treasury Holdings (Settled): 482,607,927 shares (8.82% of total issued share capital).
- Treasury Holdings (Including Unsettled): 485,507,927 shares (9.74% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,987,126,822 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 900,000 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 9.74% when including unsettled shares. The filing does not provide comparative financial data to assess changes in operating performance versus prior periods.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future guidance, outlook, risks, contingencies, or unusual items. It is a compliance disclosure confirming adherence to the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (482,607,927 settled) against the company's latest capitalization table.
- Confirm the calculation of total voting rights (9.74% held in Treasury including unsettled shares) for disclosure threshold assessments.
- Review the price paid per share (1,482 to 1,499 pence) against the market price on August 2, 2012.
- Note that this filing does not contain financial performance data; refer to the most recent Form 20-F or interim results for revenue and profit metrics.